Low vaccination rates did not rise sufficiently to attain "herd immunity" after a measles outbreak in a region in which it had been eliminated.

Multicenter study will measure efficacy, safety, and immunogenicity in adults 18–59 across Europe.

AAn expert discusses how COVID-19 has disrupted traditional respiratory virus patterns with summer surges now preceding the typical winter influenza season, while declining vaccine uptake among younger populations threatens to leave vulnerable groups increasingly exposed to seasonal illness complications.

Jacinda Abdul-Mutakabbir, PharmD, MPH, describes the university's atmosphere, students' involvement in community-based care, and the support they receive.

A June–September roundup spanning hepatitis research and surveillance data, FDA and ACIP policy moves, diet and diagnostics insights, and pipeline updates from screening innovations to HBV/HDV/HCV trials and approvals.

William Schaffner, MD, reviews clinical workup, treatment, and preventative measurements.

A June–September C diff roundup spanning diagnostics and stewardship debates, microbiome-based therapies and FMT optimization, prevention trials and funding, real-world outcomes, and persistent gaps in clinician practice and public awareness.

The 2025 ATS guidelines for community-acquired pneumonia update recommendations on imaging, antibiotic use, treatment duration, and corticosteroid use, emphasizing lung ultrasound as an alternative diagnostic tool, more selective empiric antibiotic prescribing, shorter courses of antibiotics for stable patients, and limited use of corticosteroids to severe inpatient cases.

This week, review of ACIP’s latest decisions, analysis links food insecurity with higher long COVID risk, and advocacy for immune-informed antibiotic development with updated susceptibility testing.

This newly approved long-acting injectable PrEP offers 6 months of HIV protection, and represents a major scientific and policy breakthrough. However, its success will depend on ensuring equitable access, enforcing coverage requirements, and maintaining a robust, multi-faceted HIV prevention infrastructure amid political and systemic challenges.

Nimish Patel, PharmD, discusses UC San Diego’s care offerings in HIV, the challenges of getting care to marginalized populations, and what the addition of lenacapavir means to individuals looking to access PrEP.

Environmental modeling shows inpatient IV therapy has the highest carbon, water, and waste footprint, while OPAT offers major reductions.

Panelists discuss the urgent need to ensure equitable access to novel antibiotics, highlighting global and domestic disparities, the vital role of stewardship programs, and the importance of innovative distribution models, international collaboration, and systemic reforms to bring lifesaving treatments to resource-limited settings.

Panelists discuss the complex, systemwide stewardship considerations for incorporating new antibiotics targeting resistant pathogens, emphasizing the need for real-world efficacy data, thoughtful formulary restrictions, and tailored strategies for outpatient use to ensure safe, effective, and sustainable adoption across diverse care settings.

Panelists discuss how regulatory incentives are advancing antimicrobial development, enabling a shift away from older, toxic agents like colistin, while acknowledging that despite the superiority of newer therapies, polymyxins still retain a limited role in rare, highly resistant infections where no better alternatives exist.

Panelists discuss how the clinical use of new antibiotics often extends beyond US Food and Drug Administration (FDA)–approved indications, driven by microbiological activity and clinical judgment, while highlighting the role of regulatory incentives like Qualified Infectious Disease Product (QIDP) in accelerating drug development and the need for careful, collaborative interpretation of limited trial data to ensure responsible off-label use.

Panelists discuss the challenges of implementing susceptibility testing for new antibiotics, emphasizing the need for close lab-clinician collaboration, streamlined reflex testing protocols, and investment in diagnostic infrastructure to ensure timely and effective treatment of multidrug-resistant infections.

Panelists discuss the evolving landscape of novel antibiotic combinations targeting metallo-β-lactamase (MBL)–producing and other multidrug-resistant Gram-negative bacteria, emphasizing promising early data despite limited clinical trials, the complexity of resistance mechanisms, and the potential for these therapies to improve outcomes and shape future treatment strategies.

Panelists discuss the innovative use of the aztreonam-avibactam combination to combat complex β-lactamase–mediated resistance, highlighting promising laboratory data, challenges in clinical trial enrollment for resistant infections, and the ongoing need for further research to define its role in treating multidrug-resistant Gram-negative pathogens.

Panelists discuss the real-world challenges of managing infections caused by highly resistant organisms, highlighting the impact of limited access to novel diagnostics and therapeutics, the complexities of outpatient treatment, and the urgent need for broader-spectrum agents and improved delivery methods in resource-constrained settings.

Jennifer Le, PharmD, MAS, FIDSA, FCCP, FCSHP, discusses her collaboration on this innovative work with this therapy in severely ill children.

Episode 2, Part 4, Robert Bransfield, MD, connects neural circuits, inflammatory responses to infection, and impulsivity in violent behavior.

Georges C.Benjamin, MD, executive director of the American Public Health Association, details practical implications for clinical teams.

Although the number of people with knowledge about the infection rose, the results demonstrate a continued need for further education and awareness among the public.